Bayer signs cancer collaboration with Amgen

Bayer has announced that it has agreed with Amgen to develop and commercialize a new antibody for treating cancer. Financial details of the deal were not disclosed. Under the terms of the agreement Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate.

About these ads